11. Disclosures

FSK is a clinical trial investigator for Ashibio, Incyte, Ipsen, and Regeneron; a co-inventor of U.S. Patent (Pending) to the Trustees of the University of Pennsylvania on the Use of MMP-9 Inhibitors for Heterotopic Ossification and a member of the Medical Registry Advisory Board of the IFOPA.

MAK is a clinical trial investigator for Ashibio, Incyte, Ipsen, and Regeneron.

GB is a consultant for Ipsen, Regeneron and BioMarin, has research grants and conference support from FOP France, BioMarin and Ipsen, is a member of the Advisory Boards of BioMarin and Inozyme, conducts clinical trials for Ipsen, Inozyme, BioMarin, QED, Ascendis, Alexion and Inozyme, is the PI on clinical trials for Ipsen, Inozyme, Alexion, BioMarin, Ascendis and is a member of the Board of FOP France.

AHB is a clinical trial investigator for Incyte, Ipsen, and Regeneron. MB is a clinical trial investigator for Incyte, Ipsen and Regeneron. AC- None

T-JC is a clinical trial investigator for Incyte and Ipsen.

CC - None

CLDC is a clinical trial investigator for Incyte and Ipsen and a member of the Medical Registry Advisory Board of the IFOPA.

PD is a consultant for Ipsen, a clinical trial investigator for Incyte, Ipsen, and Regeneron and a member of the Board of Directors of Tin Soldiers Global and the Noi Ci Siamo Association in Switzerland.

RJD - None

MDR was a clinical trial investigator for Regeneron.

EMWHE is a clinical trial investigator for STOPFOP, Regeneron, Ipsen, and Incyte, a member of the Medical Registry Advisory Board of the IFOPA, of the steering committee of the Amsterdam Bone Center, of the European Reference Network on rare bone diseases, a representative to the European FOP consortium, a board member NVE BoNe, and is Chair of the Rare Bone Disease Center Amsterdam UMC.

LF - None

CF is a consultant for Ipsen, Clinical Director for The Special Olympics, a member of the Board of Directors of Tin Soldiers Global and has received an honorarium from Springer for a presentation.

ZG is a consultant for the Axdev Group.

NH was a clinical investigator for Ipsen.

ECH is a clinical trial investigator and receives clinical trial support through his institution from Clementia (an Ipsen Company), Ipsen, Ascendis, and Ashibio, previously received support from Regeneron and Ultragenyx, is a member Medical Registry Advisory Board of the IFOPA, and a member of the FD/MAS Alliance Medical Advisory Board.

RK is a consultant for Ipsen, Alexion, Kyowa Kirin, UCB, Amgen and Richter, a member of the Advisory Board of Alexion, Kyowa Kirin, Theramex, a clinical investigator for Alexion, Kyowa Kirin, Incyte, Ipsen, and Regeneron, and a member of the Advisory Board of The Brittle Bone Society and the National Health Service (NHS) of England.

JK - None CL - None VM - None

RM is a consultant for Ipsen.

JCN - None

CS is a consultant for Ipsen and was a previous clinical trial investigator for Ipsen and Regeneron.

EMS - None

MAZ was a member of the Clementia/Ipsen Data Safety Monitoring Board (DSMB) during the Palovarotene clinical trials, and is currently on the Incyte DSMB

KZ is a clinical trial investigator for Incyte, Ipsen, and Regeneron.

RJP is a clinical trial investigator for Ashibio, Incyte, Ipsen, and Regeneron, a co-inventor of U.S. Patent (Pending) to the Trustees of the University of Pennsylvania on the Use of MMP-9 Inhibitors for Heterotopic Ossification, a member of the Medical Registry Advisory Board of the IFOPA, and a consultant for Incyte, Ipsen and Regeneron.